These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 29237803

  • 1. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.
    Smith KM, Fagan PC, Pomari E, Germano G, Frasson C, Walsh C, Silverman I, Bonvini P, Li G.
    Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
    [Abstract] [Full Text] [Related]

  • 2. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
    Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.
    Mol Cancer Ther; 2016 Apr; 15(4):628-39. PubMed ID: 26939704
    [Abstract] [Full Text] [Related]

  • 3. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
    Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P.
    J Med Chem; 2016 Apr 14; 59(7):3392-408. PubMed ID: 27003761
    [Abstract] [Full Text] [Related]

  • 4. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
    Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L.
    Expert Opin Investig Drugs; 2015 Apr 14; 24(11):1493-500. PubMed ID: 26457764
    [Abstract] [Full Text] [Related]

  • 5. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
    Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG.
    Cancer Discov; 2017 Apr 14; 7(4):400-409. PubMed ID: 28183697
    [Abstract] [Full Text] [Related]

  • 6. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
    Iyer R, Wehrmann L, Golden RL, Naraparaju K, Croucher JL, MacFarland SP, Guan P, Kolla V, Wei G, Cam N, Li G, Hornby Z, Brodeur GM.
    Cancer Lett; 2016 Mar 28; 372(2):179-86. PubMed ID: 26797418
    [Abstract] [Full Text] [Related]

  • 7. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
    Pacenta HL, Macy ME.
    Drug Des Devel Ther; 2018 Mar 28; 12():3549-3561. PubMed ID: 30425456
    [Abstract] [Full Text] [Related]

  • 8. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
    Yamamoto H, Nozaki Y, Sugii A, Taguchi K, Hongo T, Jiromaru R, Sato M, Nakano T, Hashimoto K, Fujiwara M, Oda Y.
    Hum Pathol; 2021 Mar 28; 109():37-44. PubMed ID: 33301751
    [Abstract] [Full Text] [Related]

  • 9. Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer.
    Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, Christiansen J, Hornby Z, Maneval EC, Multani P.
    J Natl Compr Canc Netw; 2017 Nov 28; 15(11):1317-1322. PubMed ID: 29118225
    [Abstract] [Full Text] [Related]

  • 10. Entrectinib: First Global Approval.
    Al-Salama ZT, Keam SJ.
    Drugs; 2019 Sep 28; 79(13):1477-1483. PubMed ID: 31372957
    [Abstract] [Full Text] [Related]

  • 11. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators.
    Lancet Oncol; 2020 Feb 28; 21(2):271-282. PubMed ID: 31838007
    [Abstract] [Full Text] [Related]

  • 12. Evolving role of entrectinib in treatment of NTRK-positive tumors.
    Chawla N, Bui NQ, Seetharam M.
    Future Oncol; 2021 Aug 28; 17(22):2835-2846. PubMed ID: 33896226
    [Abstract] [Full Text] [Related]

  • 13. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
    Sartore-Bianchi A, Pizzutilo EG, Marrapese G, Tosi F, Cerea G, Siena S.
    Expert Rev Anticancer Ther; 2020 May 28; 20(5):333-341. PubMed ID: 32223357
    [Abstract] [Full Text] [Related]

  • 14. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC, trial investigators.
    Lancet Oncol; 2020 Feb 28; 21(2):261-270. PubMed ID: 31838015
    [Abstract] [Full Text] [Related]

  • 15. Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.
    Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, Yano S.
    Clin Cancer Res; 2018 May 15; 24(10):2357-2369. PubMed ID: 29463555
    [Abstract] [Full Text] [Related]

  • 16. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM, Bae YH, Lee KY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Invest New Drugs; 2020 Apr 15; 38(2):360-368. PubMed ID: 31124056
    [Abstract] [Full Text] [Related]

  • 17. Prioritizing the Catalytic Gatekeepers through Pan- Inhibitory Mechanism of Entrectinib against ALK, ROS1 and TRKA Tyrosine Kinases.
    Salifu EY, Issahaku AR, Agoni C, Ibrahim MAA, Manimbulu N, Soliman MES.
    Cell Biochem Biophys; 2022 Mar 15; 80(1):11-21. PubMed ID: 35040089
    [Abstract] [Full Text] [Related]

  • 18. Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors.
    Osman HM, Tuncbilek M.
    Curr Med Chem; 2022 Mar 15; 29(15):2602-2616. PubMed ID: 34521321
    [Abstract] [Full Text] [Related]

  • 19. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
    Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E.
    Neuro Oncol; 2022 Oct 03; 24(10):1776-1789. PubMed ID: 35395680
    [Abstract] [Full Text] [Related]

  • 20. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
    Frampton JE.
    Drugs; 2021 Apr 03; 81(6):697-708. PubMed ID: 33871816
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.